Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Desloratadine.

K McClellan1, B Jarvis

  • 1Adis International Limited, Mairangi Bay, Auckland, New Zealand. demail@adis.co.nz

Drugs
|June 12, 2001
PubMed
Summary
This summary is machine-generated.

Desloratadine, a non-sedating antihistamine, effectively treats seasonal allergic rhinitis and chronic idiopathic urticaria symptoms. It demonstrates a favorable safety profile with no significant cardiovascular or psychomotor adverse effects in clinical trials.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Proton damage in (Y,Lu,Gd)<sub>3</sub>(Al,Ga)<sub>5</sub>O<sub>12</sub>:Ce mixed garnet scintillators.

The Review of scientific instruments·2022
Same author

Reconsideration of the derivation of Most Probable Numbers, their standard deviations, confidence bounds and rarity values.

Journal of applied microbiology·2015
Same author

Application of Illumina next-generation sequencing to characterize the bacterial community of the Upper Mississippi River.

Journal of applied microbiology·2013
Same author

Stachybotrys: An unusual mold associated with water-damaged buildings.

Mycotoxin research·2013
Same author

Reconsideration of the derivation of Most Probable Numbers, their standard deviations, confidence bounds and rarity values.

Journal of applied microbiology·2010
Same author

Brain sex differences and hormone influences: a moving experience?

Journal of neuroendocrinology·2009
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Pharmacology
  • Allergy and Immunology
  • Clinical Medicine

Background:

  • Desloratadine is the active metabolite of loratadine, a widely used non-sedating H1-antihistamine.
  • It is recognized for its efficacy in managing allergic conditions.
  • Understanding its safety and efficacy profile is crucial for clinical application.

Purpose of the Study:

  • To evaluate the efficacy and safety of desloratadine in patients with seasonal allergic rhinitis (SAR).
  • To assess the impact of desloratadine on patients with SAR and comorbid asthma.
  • To determine the effectiveness and tolerability of desloratadine in patients with chronic idiopathic urticaria (CIU).

Main Methods:

  • Clinical trials involving patients with SAR, SAR with asthma, and CIU.

Related Experiment Videos

  • Administration of oral desloratadine 5 mg once daily for specified durations (up to 4 weeks for SAR, 6 weeks for CIU).
  • Comparison of desloratadine treatment against placebo, with assessment of symptom reduction, quality of life, and adverse events.

    • Main Results:

    • Desloratadine significantly reduced nasal and non-nasal symptoms of SAR, improving quality of life.
    • In patients with SAR and asthma, desloratadine decreased asthma symptoms and beta2-agonist use.
    • Significant improvements in pruritus and reduction in hives were observed in CIU patients, alongside improved sleep and daytime performance.
    • Adverse event profile was comparable to placebo in all studied patient groups.

    Conclusions:

    • Desloratadine is an effective treatment for SAR and CIU, offering significant symptom relief and quality of life improvements.
    • The drug is well-tolerated and exhibits a safety profile similar to placebo, with no adverse cardiovascular or psychomotor effects at therapeutic doses.
    • Desloratadine is a valuable therapeutic option for allergic rhinitis and chronic urticaria, including in patients with coexisting asthma.